SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 5/23/2017 4:14:14 PM - Followers: 188 - Board type: Free - Posts Today: 10

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
CVM News: CEL-SCI Scientist Presents at AAI - IMMUNOLOGY 2017 Meeting 05/16/2017 08:00:00 AM
CVM News: Current Report Filing (8-k) 05/12/2017 05:24:08 PM
CVM News: CEL-SCI Announces Change to the Date of Its Annual Meeting 05/12/2017 01:00:00 PM
CVM News: Additional Proxy Soliciting Materials (definitive) (defa14a) 05/11/2017 04:19:40 PM
CVM News: Quarterly Report (10-q) 05/10/2017 04:34:38 PM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#11236   I would have agreed with you at the warfaretrader 05/23/17 04:14:14 PM
#11235   * * $CVM Video Chart 05-23-17 * * ClayTrader 05/23/17 04:14:05 PM
#11234   I'm a chartist at heart and have owned Turney 05/23/17 02:58:44 PM
#11233   I second that "Why?" Foxwoods Man 05/23/17 11:19:23 AM
#11232   Am I wrong??? Should the PPS be going PARker1703 05/23/17 10:31:37 AM
#11231   why? PARker1703 05/23/17 09:59:57 AM
#11230   This is a week we will all remember. Turney 05/23/17 09:40:06 AM
#11229   pre-market buying shurtha2000 05/23/17 09:25:23 AM
#11228   R/s listed on proxy not good stock1ace1 05/23/17 08:34:21 AM
#11227   AH buying up into the last minute interesting shurtha2000 05/23/17 12:14:59 AM
#11226   Something is brewing. Mk74 05/22/17 04:41:29 PM
#11225   * * $CVM Video Chart 05-22-17 * * ClayTrader 05/22/17 04:26:36 PM
#11224   I guess the conference had some good stuff RobotDroid 05/22/17 11:26:20 AM
#11223   This is ready shurtha2000 05/22/17 11:07:11 AM
#11222   Next week, I got that feelin' in my Turney 05/20/17 01:44:26 AM
#11221   I am not banking on anything, at least lightrock 05/18/17 09:37:53 PM
#11220   I think Leaps has a zero % chance warfaretrader 05/18/17 07:10:43 PM
#11219   It is good then to have a "whipping lightrock 05/18/17 05:56:06 PM
#11218   One would think..... trickledownfacists 05/18/17 05:53:51 PM
#11217   Yes, bad for business, that's why I would trickledownfacists 05/18/17 05:53:38 PM
#11216   That's what I used to think. But lightrock 05/18/17 05:27:36 PM
#11215   One would think that would infuriate an honest Arbitrator. Trustbaby 05/18/17 05:12:01 PM
#11214   The way I look at it is inVentiv trickledownfacists 05/18/17 05:02:53 PM
#11213   So... that suggests that Inventiv thinks they've done lightrock 05/18/17 04:49:04 PM
#11212   Very..... we shall see soon enough. trickledownfacists 05/16/17 01:04:43 PM
#11211   Interesting.... Foxwoods Man 05/16/17 11:53:22 AM
#11210   Agreed. InVentiv valued at $4.6 billion. Total trickledownfacists 05/16/17 11:16:23 AM
#11209   Trickledown sea alice 05/16/17 11:10:19 AM
#11208   CEL-SCI Scientist Presents at AAI - IMMUNOLOGY 2017 trickledownfacists 05/16/17 08:55:56 AM
#11207   Yup, correct. Your thoughts with that? trickledownfacists 05/15/17 11:56:33 PM
#11206   Any merger has each party assuming sea alice 05/15/17 11:51:07 PM
#11205   Well Warfare, whatever it is, I would watch lightrock 05/15/17 10:47:56 PM
#11204   Well Lightlock, Inventive has had years to settle warfaretrader 05/15/17 04:48:17 PM
#11203   Not sure lightrock 05/14/17 02:44:51 PM
#11202   Good point Trickle! warfaretrader 05/14/17 10:18:40 AM
#11201   Or conduct 2 mergers with other companies to trickledownfacists 05/14/17 10:03:51 AM
#11200   I think many have lost sight of the warfaretrader 05/14/17 09:24:32 AM
#11199   very interesting lightrock 05/14/17 01:36:57 AM
#11198   inVentiv announces $7.4 billion merger. http://www.fiercebiotech.com/cro/inc trickledownfacists 05/13/17 09:22:28 PM
#11197   Sorry for the misunderstanding, i do think there warfaretrader 05/13/17 07:47:31 PM
#11196   I think that's the case more than not... trickledownfacists 05/13/17 06:47:25 PM
#11195   Warfare, you don't think there's much of a Trustbaby 05/13/17 05:25:20 PM
#11194   Wow! thats all i have to say. WOW! warfaretrader 05/12/17 10:16:30 PM
#11193   I understand the doubt about us getting approval Turney 05/12/17 08:12:07 PM
#11192   Sell out to big Pharma, Now I know xdrt91 05/12/17 05:54:02 PM
#11191   Yup trickledownfacists 05/12/17 05:04:35 PM
#11190   That's true BUT he is correct...a basically completed Foxwoods Man 05/12/17 04:52:42 PM
#11189   No, I'm not kidding. We started with an Turney 05/12/17 04:39:25 PM
#11188   Turney, you are kidding right??? the xdrt91 05/12/17 03:29:32 PM
#11187   From a Friday to a Monday.... trickledownfacists 05/12/17 02:13:27 PM
PostSubject